Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers
Sponsor: AbbVie
Summary
The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity following multiple intravenous (IV) ascending doses of ABBV-8736 in healthy adult participants.
Official title: A Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of ABBV-8736 After Multiple Ascending Doses in Healthy Adult Subjects
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
24
Start Date
2025-09-02
Completion Date
2026-04
Last Updated
2026-02-23
Healthy Volunteers
Yes
Conditions
Interventions
ABBV-8736
Intravenous (IV) Infusion
Placebo
IV Infusion
Locations (1)
Acpru /Id# 277377
Grayslake, Illinois, United States